More recently, fusions involving NTRK1 and FGFR1/2/3 have been reported (Table 1), thus enlarging the spectrum of promising therapies for NSCLC (i.e. Crizotinib, Ceritinib, Alecitinib for ALK-positive NSCLC; Crizotinib for ROS1-positive NSCLC; Cabozantinib and Vandetanib for RET-positive NSCLC). Here, ALK is linked to non-small cell lung carcinoma.